◆英語タイトル:Genera Biosystems Ltd (GBI) - Product Pipeline Analysis, 2017 Update
◆商品コード:DATA8010531
◆発行会社(調査会社):
GlobalData
◆発行日:2017年12月1日
◆ページ数:39
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:医療機器
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Genera Biosystems Ltd (GBL) is a developer and commercializer of multiplexed molecular diagnostic testing products. The company offers RTIplex and PapType molecular diagnostic test. Its RTIplex is a multiplexed and automated PCR based test for detection of viral and bacterial respiratory pathogens; and PapType is a molecular diagnostic test for the detection and genotyping of high risk and low risk types of human papillomavirus that cause cervical cancer or genital warts. GBL uses AmpaSand beads technology to create identifiable clusters of beads which can be distinguished in a conventional flow cytometer. The company provides products to detect influenzaA, influenzaB, influenza A H1N1, influenzaA H5N1, respiratory syncytial virus, human metapneumovirus, adenovirus, rhinovirus, bordetella pertussis, and chlamydophila pneumonia. It collaborates with pathology customers and IVD companies. GBL is headquartered in Melbourne, Victoria, Australia.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Genera Biosystems Ltd
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Genera Biosystems Ltd Company Overview 5
Genera Biosystems Ltd Company Snapshot 5
Genera Biosystems Ltd Pipeline Products and Ongoing Clinical Trials Overview 5
Genera Biosystems Ltd – Pipeline Analysis Overview 8
Genera Biosystems Ltd – Key Facts 8
Genera Biosystems Ltd – Major Products and Services 9
Genera Biosystems Ltd Pipeline Products by Development Stage 10
Genera Biosystems Ltd Ongoing Clinical Trials by Trial Status 13
Genera Biosystems Ltd Pipeline Products Overview 15
BBVplex 15
BBVplex Product Overview 15
Diagnostic Test- Hepatitis B/C 16
Diagnostic Test- Hepatitis B/C Product Overview 16
Diagnostic Test- Herpes Simplex Virus (HSV) 1 / HSV 2 17
Diagnostic Test- Herpes Simplex Virus (HSV) 1 / HSV 2 Product Overview 17
Gen-plex 18
Gen-plex Product Overview 18
Gen-plex Clinical Trial 19
PapType 20
PapType Product Overview 20
PapType Clinical Trial 21
PapType SP 22
PapType SP Product Overview 22
QSand Platform 23
QSand Platform Product Overview 23
STIplex 24
STIplex Product Overview 24
Genera Biosystems Ltd – Key Competitors 25
Genera Biosystems Ltd – Key Employees 26
Genera Biosystems Ltd – Locations And Subsidiaries 27
Head Office 27
Recent Developments 28
Genera Biosystems Ltd, Recent Developments 28
Nov 15, 2016: Genera Lodges 2016 Tax Return – To Receive $752k R&D Tax Rebate 28
Oct 03, 2016: Genera Biosystems: 2016 Annual Report Highlights 28
Oct 03, 2016: Genera Biosystems Limited Receipt Of Data For Paptype 2,000 Specimens In US Based Screening Population 29
Jun 21, 2016: Genera Biosystems provides update on PapType HPV test 31
Jun 21, 2016: Genera Biosystems Receives Regulatory Approval For Its Multiplex Molecular Diagnostics Test RTI-plex 31
Aug 07, 2015: Genera Biosystems: Receipt Of Predictors 3 Clinical Data 32
Sep 03, 2014: Genera Biosystems provides update on multiplex diagnostic assay STIplex 33
Sep 03, 2014: Genera Biosystems to Submit TGA Application for Conformity Assesment for Multiplex Molecular Diagnostics Test RTI-Plex 33
Sep 03, 2014: Genera Lodges TGA Application For Conformity Assesment for PapType HPV assay 34
Apr 29, 2014: Genera Biosystems Welcomes Australian MSAC Recommendation For Hpv Testing As Primary Cervical Cancer Screening Tool 34
Appendix 36
Methodology 36
About GlobalData 38
Contact Us 38
Disclaimer 39
List of Tables
Genera Biosystems Ltd Pipeline Products and Ongoing Clinical Trials Overview 5
Genera Biosystems Ltd Pipeline Products by Equipment Type 6
Genera Biosystems Ltd Pipeline Products by Indication 7
Genera Biosystems Ltd Ongoing Clinical Trials by Trial Status 7
Genera Biosystems Ltd, Key Facts 8
Genera Biosystems Ltd, Major Products and Services 9
Genera Biosystems Ltd Number of Pipeline Products by Development Stage 10
Genera Biosystems Ltd Pipeline Products Summary by Development Stage 11
Genera Biosystems Ltd Ongoing Clinical Trials by Trial Status 13
Genera Biosystems Ltd Ongoing Clinical Trials Summary 14
BBVplex - Product Status 15
BBVplex - Product Description 15
Diagnostic Test- Hepatitis B/C - Product Status 16
Diagnostic Test- Hepatitis B/C - Product Description 16
Diagnostic Test- Herpes Simplex Virus (HSV) 1 / HSV 2 - Product Status 17
Diagnostic Test- Herpes Simplex Virus (HSV) 1 / HSV 2 - Product Description 17
Gen-plex - Product Status 18
Gen-plex - Product Description 18
Gen-plex - Predictors 3 Study 19
PapType - Product Status 20
PapType - Product Description 20
PapType - Predictors 3 Study 21
PapType SP - Product Status 22
PapType SP - Product Description 22
QSand Platform - Product Status 23
QSand Platform - Product Description 23
STIplex - Product Status 24
STIplex - Product Description 24
Genera Biosystems Ltd, Key Employees 26
Glossary 37